Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases

Current Atherosclerosis Reports

Volumn 8, Issue 2, 2006, Pages 163-167

  Calabresi, Laura ^a   Sirtori, Cesare R ^b   Paoletti, Rodolfo ^b   Franceschini, Guido ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARGININE; ATORVASTATIN; CYSTEINE; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; APOLIPOPROTEIN A I MILANO; APOLIPOPROTEIN A-I MILANO;

ACUTE CORONARY SYNDROME; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FIBRINOLYSIS; GENETIC VARIABILITY; HEART PROTECTION; HETEROZYGOSITY; HUMAN; INTRAVASCULAR ULTRASOUND; NONHUMAN; RABBIT; RAT; REPERFUSION INJURY; RESTENOSIS; REVIEW; TREATMENT OUTCOME; ANIMAL; BLOOD; DRUG EFFECT;

ANIMALS; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; TREATMENT OUTCOME;

EID: 33645090443     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0054-4     Document Type: Review

References (43)

1. Franceschini G: Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001, 88:9-13.
2. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
3. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
4. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
5. Taylor AJ, Sullenberger LE, Lee HJ, et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
6. Whitney EJ, Krasuski PA, Personius BE, et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
7. Paszty C, Maeda N, Verstuyft J, Rubin EM: Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994, 94:899-903.
8. Franceschini G, Maderna P, Sirtori CR: Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis 1991, 88:99-107.
9. Barter PJ, Nicholls S, Rye KA, et al.: Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
10. Calabresi L, Gomaraschi M, Franceschini G: Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003, 23:1724-1731.
11. Rye KA, Barter PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24:421-428.
12. Franceschini G, Sirtori CR, Capurso A, et al.: A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an italian family. J Clin Invest 1980, 66:892-900.
13. Weisgraber KH, Rall SC Jr, Bersot TP, et al.: Apolipoprotein AIMilano. Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J Biol Chem 1983, 258:2508-2513.
14. Franceschini G, Sirtori CR, Bosisio E, et al.: Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis 1985, 58:159-174.
15. Gualandri V, Franceschini G, Sirtori CR, et al.: A-IMilano apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985, 37:1083-1097.
16. Sirtori CR, Calabresi L, Franceschini G, et al.: Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant. The Limone sul Garda Study. Circulation 2001, 103:1949-1954.
17. Franceschini G, Calabresi L, Chiesa G, et al.: Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999, 19:1257-1262.
18. Calabresi L, Canavesi M, Bernini F, Franceschini G: Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. Biochemistry 1999, 38:16307-16314.
19. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234-1241.
20. Jonas A: Reconstitution of high-density lipoproteins. Methods Enzymol 1986, 128:553-582.
21. Calabresi L, Gomaraschi M, Rossoni G, Franceschini G: Synthetic high density lipoproteins as cardioprotective agents against ischemia/reperfusion injury. Pharmacol Ther 2005, In press.
22. Calabresi L, Vecchio G, Longhi R, et al.: Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem 1994, 269:32168-32174.
23. Shah PK, Nilsson J, Kaul S, et al.: Effects of recombinant apolipoprotein A-I-Milano on aortic atherosclerosis in apolipoportein E-deficient mice. Circulation 1998, 97:780-785.
24. Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001, 103:3047-3050.
25. Chiesa G, Rigamonti E, Monteggia E, et al.: Evaluation of a soft atherosclerotic lesion in the rabbit aorta by an invasive IVUS method versus a non-invasive MRI technology. Atherosclerosis 2004, 174:25-33.
26. Chiesa C, Monteggia E, Marchesi M, et al.: Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90:974-980.
27. Ameli S, Hultgardh Nilsson A, Cercek B, et al.: Recombinant apolipoprotein A-IMilano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994, 90:1935-1941.
28. Soma MR, Donetti E, Parolini C, et al.: Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995, 76:405-411.
29. Kaul S, Rukshin V, Santos R, et al.: Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003, 107:2551-2554.
30. Calabresi L, Franceschini G, Sirtori CR, et al.: Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997, 238:61-65.
31. Nilsson J, Dahlgren B, Ares M, et al.: Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. Arterioscler Thromb Vasc Biol 1998, 18:13-19.
32. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML: Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985, 39:1-8.
33. Li D, Weng S, Yang B, et al.: Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999, 19:378-383.
34. Mineo C, Shaul PW: HDL stimulation of endothelial nitric oxide synthase. A novel mechanism of HDL action. Trends Cardiovasc Med 2003, 13:226-231.
35. Calabresi L, Rossoni G, Gomaraschi M, et al.: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003, 92:330-337.
36. Rossoni G, Gomaraschi M, Berti F, et al.: Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. J Pharmacol Exp Ther 2004, 308:79-84.
37. Marchesi M, Booth EA, Davis T, et al.: Apolipoprotein A-IMilano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury. J Pharmacol Exp Ther 2004, 311:1023-1031.
38. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
39. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
40. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
41. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
42. Navab M, Anantharamaiah GM, Reddy ST, et al.: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325-1331.
43. Rodrigueza WV, Mazany KD, Essenburg AD, et al.: Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:2132-2139.